EDIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Editas Medicine Inc (EDIT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While hedge funds are increasing their positions, the stock's recent price performance, lack of positive news catalysts, and weak financial performance make it prudent to wait for a clearer entry point or improved fundamentals.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 38.986, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 1.805, with resistance at 2.24. The price has dropped significantly (-13.47%) in the regular market session, suggesting bearish sentiment.
Hedge funds have increased their buying activity by 500.44% over the last quarter, indicating institutional interest.
The stock has experienced a significant price drop (-13.47%) in the regular market session. Financial performance shows a sharp decline in net income (-59.58% YoY) and EPS (-62.67% YoY). No recent news or congress trading data to support a positive outlook.
In Q3 2025, revenue increased significantly by 12265.57% YoY to $7.54M, but net income dropped to -$25.12M (-59.58% YoY), and EPS fell to -0.28 (-62.67% YoY). Gross margin remains at 100%, but the company is still unprofitable.
No recent analyst rating or price target changes available for evaluation.
